FarmaMondo S.A. exclusively supplies BiCNU® (Carmustine for Injection) on an early access basis to Swiss healthcare providers.
The worldwide rights for BiCNU® were acquired by Emcure Pharmaceuticals in January 2013 from Bristol-Myers Squibb.
The product is available for Switzerland exclusively via FarmaMondo S.A., on a named-patient basis.
As per SPC of the UK approved product, BiCNU® (Carmustine for injection) is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in Brain tumors – (glioblastoma, medulloblastoma, astrocytoma and metastatic brain tumors), Multiple myeloma, Hodgkin’s disease and Non-Hodgkin’s lymphomas.
For all inquiries regarding BiCNU®, please contact: Irene Sánchez – Program Manager, BiCNU® Swiss Access.
Phone: +41 91 6976392
About Emcure pharmaceuticals and Konsina: Emcure Pharmaceuticals is a a Pune-based drug maker, which recently estimated its annual global sales at over $670 million, has widened its businesses from contract manufacturing to a strong presence in the domestic, US and European markets. The company, incorporated in 1981, makes a range of drugs such as Asomex, used to treat blood pressure. Cardiology, gynaecology and anti-infective medicines account for a bulk of its portfolio. Konsina is the European arm of Emcure, a joint venture, targeted for the commercialization of the BiCNU therapy in EU markets.
About Farmamondo: Farmamondo is a Swiss-based pharmaceutical company with a focus on providing patient access to their unmet medical need via Early-access, Named-patient and Compassionate-use programs. Our global footprint includes commercial operations in more than 50 markets, headquartered from Switzerland with regional hubs in Europe, Asia and Latin America.